Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Amrubicin
Sponsor: Celgene Corporation